1 Independent Writer and Researcher, Innovation in Global Governance for Science, Technology and Health, Toronto, Ontario, Canada .
2 School of Biotechnology, Amrita Vishwa Vidyapeetham (Amrita University) , Kollam, India .
OMICS. 2017 Nov;21(11):633-637. doi: 10.1089/omi.2017.0148. Epub 2017 Oct 24.
Original ideas and innovation cannot always be ordered like a courier service and delivered fresh to our desk at 9 am. Yet, most creativity-based organizations, careers, and professions, science and biotechnology innovation included, emphasize the speed as the prevailing ideology. But a narrow focus on speed has several and overlooked shortcomings. For example, it does not offer the opportunity to draw from, and stitch together disparate concepts and practices for truly disruptive innovation. Preventing false starts, learning from others' or our own mistakes, and customizing innovations for local community needs are difficult in a speed-hungry innovation ecosystem. We introduce a new strategy, the Fast-Second Winner, specifically in relation to global development of biotechnologies and precision medicine. This à la carte global development strategy envisions a midstream entry into the innovation ecosystem. Moreover, we draw from the works of the late David Bowie who defied rigid classifications as an artist and prolific innovator, and introduce the concept and practice of slow innovation that bodes well with the Fast-Second Winner strategy. A type of slow innovation, the Fast-Second Winner is actually fast and sustainable in the long term, and efficient by reducing false starts in new precision medicine application contexts and geographies, learning from other innovators' failures, and shaping innovations for the local community needs. The establishment of Centers for Fast-Second Innovation (CFSIs), and their funding, for example, by crowdfunding and other innovative mechanisms, could be timely for omics and precision medicine global development. If precision medicine is about tailoring drug treatments and various health interventions to individuals, we suggest to start from tailoring new ideas, and focus not only on how much we innovate but also what and how we innovate. In principle, the Fast-Second Winner can be applied to omics and other biotechnology responsible development in medical practice or any field of applied innovation.
原创想法和创新不能总是像快递服务一样，在早上 9 点准时送到我们的办公桌上。然而，大多数以创造力为基础的组织、职业和专业，包括科学和生物技术创新，都强调速度是主导思想。但是，对速度的狭隘关注有几个被忽视的缺点。例如，它没有提供机会，从不同的概念和实践中汲取灵感，并将其整合在一起，以实现真正的颠覆性创新。在一个热衷于速度的创新生态系统中，防止错误的开始、从他人或自己的错误中学习以及为当地社区的需求定制创新都是很困难的。我们引入了一种新策略，即“快速第二赢家”，特别是在全球生物技术和精准医学的发展方面。这种定制化的全球发展策略设想在创新生态系统中进行中游进入。此外，我们借鉴了已故大卫·鲍伊的作品，他拒绝了作为一名艺术家和多产创新者的僵化分类，并引入了慢创新的概念和实践，这与“快速第二赢家”策略相得益彰。作为一种慢创新，“快速第二赢家”实际上在长期内是快速和可持续的，并且通过减少新的精准医学应用背景和地理环境中的错误开始、从其他创新者的失败中学习以及为当地社区的需求塑造创新，具有效率。例如，通过众筹和其他创新机制，为快速第二创新中心（CFSIs）的建立及其提供资金，可能会及时促进组学和精准医学的全球发展。如果精准医学是关于为个人量身定制药物治疗和各种健康干预措施，那么我们建议从量身定制新想法开始，不仅关注我们创新的多少，还要关注我们创新的内容和方式。原则上，“快速第二赢家”可以应用于医学实践或任何应用创新领域的组学和其他生物技术的负责任发展。
